113 related articles for article (PubMed ID: 19302507)
1. Type-I interferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients.
Shiba M; Nonomura N; Nakai Y; Nakayama M; Takayama H; Inoue H; Tsujimura A; Nishimura K; Okuyama A
Int J Urol; 2009 Apr; 16(4):356-9. PubMed ID: 19302507
[TBL] [Abstract][Full Text] [Related]
2. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
Sakaguchi M; Kubota S; Nishikido M; Taniguchi K; Inuzuka S; Saito Y; Kanetake H; Koga S
Int J Mol Med; 2002 Sep; 10(3):317-20. PubMed ID: 12165807
[TBL] [Abstract][Full Text] [Related]
3. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance.
Shang D; Liu Y; Ito N; Kamoto T; Ogawa O
Cancer Sci; 2007 Aug; 98(8):1259-64. PubMed ID: 17573897
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Van Gool AR; Verkerk R; Fekkes D; Bannink M; Sleijfer S; Kruit WH; van der Holt B; Scharpé S; Eggermont AM; Stoter G; Hengeveld MW
Psychiatry Clin Neurosci; 2008 Oct; 62(5):597-602. PubMed ID: 18950381
[TBL] [Abstract][Full Text] [Related]
5. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
[TBL] [Abstract][Full Text] [Related]
6. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma.
Shimazui T; Kojima T; Yoshikawa K; Ami Y; Oikawa T; Uchida K; Akaza H
Cancer Sci; 2009 Sep; 100(9):1714-8. PubMed ID: 19496784
[TBL] [Abstract][Full Text] [Related]
7. Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.
Ota H; Nagano H; Doki Y; Sekimoto M; Kondo M; Wada H; Nakamura M; Noda T; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Dono K; Umeshita K; Nakamori S; Wakasa K; Sakon M; Monden M
Oncol Rep; 2006 Aug; 16(2):249-55. PubMed ID: 16820899
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
Tatsugami K; Eto M; Harano M; Hamaguchi M; Miyamoto T; Morisaki T; Furue M; Akashi K; Naito S
Int J Urol; 2008 Aug; 15(8):694-8. PubMed ID: 18564205
[TBL] [Abstract][Full Text] [Related]
9. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
11. [Expression of IFN-alpha/beta receptor in the PBMCs and liver of patients with hepatitis B and its clinical significance].
Fan HB; Guo YB; Wang BJ; Zhu YF; Wu AH; Hou JL; Yang DL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):979-81. PubMed ID: 18583243
[TBL] [Abstract][Full Text] [Related]
12. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells.
Damdinsuren B; Nagano H; Wada H; Kondo M; Ota H; Nakamura M; Noda T; Natsag J; Yamamoto H; Doki Y; Umeshita K; Dono K; Nakamori S; Sakon M; Monden M
Int J Oncol; 2007 Jan; 30(1):201-8. PubMed ID: 17143530
[TBL] [Abstract][Full Text] [Related]
13. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.
Wittnebel S; Jalil A; Thiery J; DaRocha S; Viey E; Escudier B; Chouaib S; Caignard A
Eur Cytokine Netw; 2005 Jun; 16(2):123-7. PubMed ID: 15941683
[TBL] [Abstract][Full Text] [Related]
15. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
[TBL] [Abstract][Full Text] [Related]
16. A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets.
Tochizawa S; Akamatsu S; Sugiyama Y; Muraguchi M; Ohmoto Y; Ono Y; Ishikawa H; Tanigami A; Sumida T; Mori T
J Pharmacol Toxicol Methods; 2004; 50(1):59-66. PubMed ID: 15233969
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
Kawai S; Azuma Y; Fujii E; Furugaki K; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Cancer Sci; 2008 Dec; 99(12):2461-6. PubMed ID: 19032371
[TBL] [Abstract][Full Text] [Related]
18. Muscle and small intestinal metastasis of renal cell carcinoma markedly responsive to interferon-alpha therapy: a case report.
Sano F; Kimura R; Fujikawa N; Sugiura S; Hirai K; Ueki T; Kitami K
Hinyokika Kiyo; 2007 Sep; 53(9):635-9. PubMed ID: 17933140
[TBL] [Abstract][Full Text] [Related]
19. Modulation of IgG and complement receptor expression of phagocytes in kidney cancer patients during treatment with interferon-alpha.
Salminen E; Kankuri M; Nuutila J; Lilius EM; Pellimiemi TT
Anticancer Res; 2001; 21(3B):2049-55. PubMed ID: 11497297
[TBL] [Abstract][Full Text] [Related]
20. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
